Cargando…
PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK
Background: In addition to protein tyrosine kinases, accumulating evidence has shown that protein tyrosine phosphatases (PTPs) are suitable therapeutic targets in cancer. PRL-3 is a PTP member that has been well studied in many malignant tumours. The goal of the present study was to elucidate the ro...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481414/ https://www.ncbi.nlm.nih.gov/pubmed/32929353 http://dx.doi.org/10.7150/thno.42069 |
_version_ | 1783580598402547712 |
---|---|
author | Zhou, Qiming Zhou, Qianlei Liu, Qinghua He, Zhanghai Yan, Yongcong Lin, Jianhong Chen, Zheng He, Chuanchao Mao, Kai Wang, Jie Zhou, Zhenyu Xiao, Zhiyu Zhang, Jianlong |
author_facet | Zhou, Qiming Zhou, Qianlei Liu, Qinghua He, Zhanghai Yan, Yongcong Lin, Jianhong Chen, Zheng He, Chuanchao Mao, Kai Wang, Jie Zhou, Zhenyu Xiao, Zhiyu Zhang, Jianlong |
author_sort | Zhou, Qiming |
collection | PubMed |
description | Background: In addition to protein tyrosine kinases, accumulating evidence has shown that protein tyrosine phosphatases (PTPs) are suitable therapeutic targets in cancer. PRL-3 is a PTP member that has been well studied in many malignant tumours. The goal of the present study was to elucidate the role of PRL-3 in hepatocellular carcinoma (HCC), which remains largely unknown. Methods: Bioinformatic and immunohistochemical analyses were performed to analyse PRL-3 expression in HCC tissue samples and determine its clinical relevance. PRL-3 gene copy number variations were evaluated by bioinformatic analysis and quantitative-genomic polymerase chain reaction. The biological functions of PRL-3 were investigated in vivo and vitro. Gene microarray assays, RT-qPCR, western blotting and luciferase experiments were performed to identify the downstream effectors of PRL-3 that mediate its functions in HCC. Results: PRL-3 expression was upregulated in HCC samples from public databases and in cohort samples from our centre. High PRL-3 expression was associated with poor prognosis. Copy number gains and amplification of chromosome 8q24.3 in HCC were determined to be positively correlated with the PRL-3 overexpression. PRL-3 overexpression promoted HCC cell proliferation, migration and adhesion, while its loss had the opposite effects. Further study showed that focal adhesion kinase (FAK) was co-amplified and co-expressed with PRL-3 in HCC. Interestingly, PRL-3 also promoted the phosphorylation of FAK, which subsequently mediated the oncogenic functions of PRL-3 in HCC cells. Moreover, TGFB1 was identified as a downstream molecule of PRL-3. TGF-β signalling was shown to mediate the PRL-3-induced activation of FAK. Furthermore, the p38 and PI3K/AKT pathways were observed to mediate the PRL-3-induced expression of TGFB1 and the subsequent activation of FAK, while the activation of FAK in turn stimulated activation of the p38 and PI3K/AKT pathways, forming a PRL-3-triggered AKT/p38/TGFB1/FAK positive feedback loop. Conclusion: Collectively, our findings indicate that the PTP PRL-3 plays a crucial role in the progression of HCC and provides an example of how co-amplified genes work together in HCC. |
format | Online Article Text |
id | pubmed-7481414 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-74814142020-09-13 PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK Zhou, Qiming Zhou, Qianlei Liu, Qinghua He, Zhanghai Yan, Yongcong Lin, Jianhong Chen, Zheng He, Chuanchao Mao, Kai Wang, Jie Zhou, Zhenyu Xiao, Zhiyu Zhang, Jianlong Theranostics Research Paper Background: In addition to protein tyrosine kinases, accumulating evidence has shown that protein tyrosine phosphatases (PTPs) are suitable therapeutic targets in cancer. PRL-3 is a PTP member that has been well studied in many malignant tumours. The goal of the present study was to elucidate the role of PRL-3 in hepatocellular carcinoma (HCC), which remains largely unknown. Methods: Bioinformatic and immunohistochemical analyses were performed to analyse PRL-3 expression in HCC tissue samples and determine its clinical relevance. PRL-3 gene copy number variations were evaluated by bioinformatic analysis and quantitative-genomic polymerase chain reaction. The biological functions of PRL-3 were investigated in vivo and vitro. Gene microarray assays, RT-qPCR, western blotting and luciferase experiments were performed to identify the downstream effectors of PRL-3 that mediate its functions in HCC. Results: PRL-3 expression was upregulated in HCC samples from public databases and in cohort samples from our centre. High PRL-3 expression was associated with poor prognosis. Copy number gains and amplification of chromosome 8q24.3 in HCC were determined to be positively correlated with the PRL-3 overexpression. PRL-3 overexpression promoted HCC cell proliferation, migration and adhesion, while its loss had the opposite effects. Further study showed that focal adhesion kinase (FAK) was co-amplified and co-expressed with PRL-3 in HCC. Interestingly, PRL-3 also promoted the phosphorylation of FAK, which subsequently mediated the oncogenic functions of PRL-3 in HCC cells. Moreover, TGFB1 was identified as a downstream molecule of PRL-3. TGF-β signalling was shown to mediate the PRL-3-induced activation of FAK. Furthermore, the p38 and PI3K/AKT pathways were observed to mediate the PRL-3-induced expression of TGFB1 and the subsequent activation of FAK, while the activation of FAK in turn stimulated activation of the p38 and PI3K/AKT pathways, forming a PRL-3-triggered AKT/p38/TGFB1/FAK positive feedback loop. Conclusion: Collectively, our findings indicate that the PTP PRL-3 plays a crucial role in the progression of HCC and provides an example of how co-amplified genes work together in HCC. Ivyspring International Publisher 2020-08-18 /pmc/articles/PMC7481414/ /pubmed/32929353 http://dx.doi.org/10.7150/thno.42069 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Zhou, Qiming Zhou, Qianlei Liu, Qinghua He, Zhanghai Yan, Yongcong Lin, Jianhong Chen, Zheng He, Chuanchao Mao, Kai Wang, Jie Zhou, Zhenyu Xiao, Zhiyu Zhang, Jianlong PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK |
title | PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK |
title_full | PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK |
title_fullStr | PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK |
title_full_unstemmed | PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK |
title_short | PRL-3 facilitates Hepatocellular Carcinoma progression by co-amplifying with and activating FAK |
title_sort | prl-3 facilitates hepatocellular carcinoma progression by co-amplifying with and activating fak |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481414/ https://www.ncbi.nlm.nih.gov/pubmed/32929353 http://dx.doi.org/10.7150/thno.42069 |
work_keys_str_mv | AT zhouqiming prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT zhouqianlei prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT liuqinghua prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT hezhanghai prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT yanyongcong prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT linjianhong prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT chenzheng prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT hechuanchao prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT maokai prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT wangjie prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT zhouzhenyu prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT xiaozhiyu prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak AT zhangjianlong prl3facilitateshepatocellularcarcinomaprogressionbycoamplifyingwithandactivatingfak |